ESMO 2016 – Congress Highlights
Kinesys Oncology: ESMO Congress, Copenhagen, 7-11 October 2016 Update on Lung Cancers, plus selected highlights in other tumours Lung Cancer: http://emarketing.atalanta.uk.com/t/y-F1A2BEE45251C66C RCC, Prostate, SCLC, Gastro-Oesophageal Cancers: http://emarketing.atalanta.uk.com/t/y-0F73DC93CC39BBDA NSCLC AstraZeneca: Selumetinib misses primary endpoint. Durvalumab: 80%, 6-month survival in Phase I / II